Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 41412 matches for

Exscientia, the leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD).

brain

AI Meeting Tools Privacy Notice

NDM policy document explaining the use of AI tools in meetings

NDM_AI_meeting_tools_privacy_notice_may25.pdf (168 KB)

career_track_proposal

Aug 23 NDM Career Track Proposal Ext 1.1.pdf (142 KB)

NDM Principal Investigator Career Development Scheme

Aug 23 NDM Career Track Proposal Ext 1.1.pdf (142 KB)

2023_03_13SymptomsinCovidnegativesforwebsite.pdf

2023_03_13SymptomsinCovidnegativesforwebsite.pdf (103 KB)

Protocolv22.020230202.pdf

Protocolv22.020230202.pdf (3 MB)

2023_03_06SymptomsinCovidnegativesforwebsite.pdf

2023_03_06SymptomsinCovidnegativesforwebsite.pdf (120 KB)

2023_02_27SymptomsinCovidnegativesforwebsite.pdf

2023_02_27SymptomsinCovidnegativesforwebsite.pdf (118 KB)

2023_02_20SymptomsinCovidnegativesforwebsite.pdf

2023_02_20SymptomsinCovidnegativesforwebsite.pdf (114 KB)

2023_02_13SymptomsinCovidnegativesforwebsite.pdf

2023_02_13SymptomsinCovidnegativesforwebsite.pdf (118 KB)

2023_01_30SymptomsinCovidnegativesforwebsite.pdf

2023_01_30SymptomsinCovidnegativesforwebsite.pdf (116 KB)

2023_02_06SymptomsinCovidnegativesforwebsite.pdf

2023_02_06SymptomsinCovidnegativesforwebsite.pdf (117 KB)

2023_01_23SymptomsinCovidnegativesforwebsite.pdf

2023_01_23SymptomsinCovidnegativesforwebsite.pdf (117 KB)

2023_01_16SymptomsinCovidnegativesforwebsite.pdf

2023_01_16SymptomsinCovidnegativesforwebsite.pdf (278 KB)

2023_01_09SymptomsinCovidnegativesforwebsite.pdf

2023_01_09SymptomsinCovidnegativesforwebsite.pdf (182 KB)

2022_12_28SymptomsinCovidnegativesforwebsite.pdf

2022_12_28SymptomsinCovidnegativesforwebsite.pdf (137 KB)

2022_12_12SymptomsinCovidnegativesforwebsite.pdf

2022_12_12SymptomsinCovidnegativesforwebsite.pdf (153 KB)

2022_12_05SymptomsinCovidnegativesforwebsite.pdf

2022_12_05SymptomsinCovidnegativesforwebsite.pdf (159 KB)

2022_12_05SymptomsinCovidnegativesforwebsite.pdf

2022_12_05SymptomsinCovidnegativesforwebsite.pdf (154 KB)

Scoring guidelines

AnnexeAScoringGuidelinesfor2023_forweb.pdf (263 KB)

1922CISDBloodGuideWelshProtocol21.1OnlineA.pdf

1922CISDBloodGuideWelshProtocol21.1OnlineA.pdf (4 MB)

Load More

Similar stories

Nigeria rolls out new Oxford R21 malaria vaccine

On Thursday, Nigeria announced the regulatory approval and launch of the new R21/Matrix-M™ malaria vaccine that will be freely administered to recipients. This marks a significant milestone in the country’s fight against the deadly disease.

Developing the first cancer prevention vaccine for Lynch syndrome

PSI collaborates with Oxford's History of Science Museum on new exhibition

Côte d’Ivoire becomes first nation to deploy R21 malaria vaccine

Caesar Atuire appointed International Association of Bioethics President

Bangladesh Health Minister visits the Centre for Medicines Discovery